Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
CIVITAS SOLUTIONS Aktie jetzt für 0€ handeln |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
DEXCOM | 57,25 | +2,10 % | Medtronic, Masimo, Dexcom CEOs share tips on medtech leadership | ||
PLUS THERAPEUTICS | 0,699 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer | HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed... ► Artikel lesen | |
CARDINAL HEALTH | 136,00 | +0,67 % | Cardinal Health launches a new all-in-one solution for deep vein thrombosis and pulmonary embolism prevention | Kendall SCD SmartFlow Compression System is now available in Europe.
DUBLIN, Oct. 7, 2025 /PRNewswire/ -- Cardinal Health has announced the international launch of... ► Artikel lesen | |
DAVITA | 106,30 | -0,42 % | Aktienmarkt: DaVita-Aktie tritt auf der Stelle (110,9548 €) | Wenig Kursbewegung zur Stunde bei der Aktie von DaVita . Das Wertpapier notiert derzeit bei 130,14 US-Dollar. Der Kurs der Aktie von DaVita zeigt sich aktuell kaum verändert im Vergleich zu der Schlussnotierung... ► Artikel lesen | |
EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting | -- Special Meeting to be held on September 26, 2025 --
SAN DIEGO, Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders today, Evofem Biosciences, Inc.... ► Artikel lesen | |
DENTSPLY SIRONA | 10,380 | +1,76 % | DENTSPLY SIRONA Inc.: Dentsply Sirona Appoints Aldo M. Denti as Chief Commercial Officer and Announces Customer-Centric Organization | CHARLOTTE, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced that Aldo M. Denti has been appointed Executive Vice President... ► Artikel lesen | |
CENTENE | 31,010 | +0,71 % | Centene stock price target maintained at $38 by Cantor Fitzgerald | ||
CYTOSORBENTS | 0,800 | +2,17 % | CytoSorbents Corporation: CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR | FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authorization... ► Artikel lesen | |
COOPER COMPANIES | 58,50 | -0,85 % | Cooper Companies-Aktie verliert 5,17 Prozent (55,00 €) | Die Aktie von Cooper Companies notiert am Dienstag leichter. Zuletzt zahlten Investoren für die Aktie 55,00 Euro. Für Inhaber von Cooper Companies ist der heutige Handelstag bisher nicht sonderlich... ► Artikel lesen | |
FULGENT GENETICS | 19,000 | -2,06 % | Fulgent Genetics: A Risky Bet or a Hidden Gem? | ||
EKSO BIONICS | 4,935 | 0,00 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Second Quarter 2025 Financial Results | SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
IMUNON | 4,460 | 0,00 % | Imunon, Inc.: IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement | LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company... ► Artikel lesen | |
DELCATH SYSTEMS | 9,550 | +5,52 % | Delcath Systems, Inc.: Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress | Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the acceptance of an oral presentation on... ► Artikel lesen | |
CAREDX | 12,520 | -0,87 % | CareDx, Inc.: CareDx präsentiert neue IVD-Produkte und IVDR-Zertifizierung für AlloSeq Tx und QTYPE bei der Jahrestagung 2025 der American Society of Histocompatibility & Immunogenetics | Festigung der weltweiten Führungsrolle bei der HLA-Typisierung von Spenderorganen und Transplantatempfängern
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company ein führendes Unternehmen auf dem... ► Artikel lesen | |
NUWELLIS, INC | 3,490 | 0,00 % | Nuwellis, Inc. - 8-K, Current Report |